Thumb Arthritis Market Trends

Global Thumb Arthritis Market Overview

Thumb Arthritis Market Size was valued at USD 0.4 Billion in 2022. The thumb arthritis market industry is projected to grow from USD 0.43 Billion in 2023 to USD 0.833 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.50% during the forecast period (2023 - 2032). 

The main market driver propelling the growth of the thumb arthritis market is the rising prevalence of thumb arthritis. Healthcare costs and the growing geriatric and obese populations are anticipated to drive market expansion over the study period. Additionally, boosting investment in R&D efforts and introducing novel approaches to treating thumb arthritis may present a chance to accelerate market expansion.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In May 2024, Teva and Alvotech announced the US launch of SIMLANDI (adalimumab-ryvk) injection, an interchangeable biosimilar to the reference product Humira, for the treatment of arthritis. This is the inaugural biosimilar to be introduced as part of the strategic partnership between the two organizations. For the 40mg/0.4ml injection, SIMLANDI has been authorized by the US Food and Drug Administration (FDA) as the first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity. 

It is recommended for the treatment of a variety of adult inflammatory conditions, such as adolescent idiopathic arthritis, rheumatoid arthritis in adults, psoriatic arthritis, and Crohn's disease. Teva and Alvotech entered into a strategic partnership in August 2020 to exclusively market five biosimilar product candidates from Alvotech. In July of the previous year, the collaboration was extended to include two additional biosimilars and novel presentations of two previously collaborated products. 

The development and manufacturing of these products are the responsibility of Alvotech, while Teva is responsible for their exclusive commercialization in the United States, utilizing its sales and marketing capabilities. The successful launch and distribution of SIMLANDI are guaranteed by the partnership, which capitalizes on Teva's extensive sales and marketing infrastructure.

Thumb Arthritis Market Trends

• Growing aging population is driving the market growth

The majority of people with thumb arthritis are over 40, and the world's population is ageing significantly. Arthritis may develop in the thumb joint as people age due to wear and tear over time. The market for choices for diagnosis, treatment, and management of thumb arthritis is directly impacted by this rise in prevalence. Additionally, ageing is linked to the body's normal degenerative processes, which include alterations to the joints. The cartilage in the thumb joint may deteriorate with time, resulting in the onset of thumb arthritis. Factors including prior injuries, a hereditary propensity, or repetitive use of the thumb joint might worsen these degenerative changes. Treatments for thumb arthritis are now more widely available to a bigger population due to rising healthcare costs and the availability of medical insurance. The market CAGR for thumb arthritis has risen as a result of this.

The market for thumb arthritis is significantly influenced by changes in lifestyle. Many people today lead sedentary lifestyles with little to no physical activity. Weak muscles, inadequate joint support, and increased stress on the thumb joint can all be results of inactivity. The onset or course of thumb arthritis might be influenced by a lack of consistent physical activity. Additionally, obesity is becoming more and more commonplace in the world. The thumb joint is particularly stressed by excess body weight, which accelerates cartilage deterioration and wear. Inflammation and joint damage can be brought on by poor dietary decisions, such as a high intake of processed foods, saturated fats, and sugary beverages. Some meals, such as those rich in purines, which are present in red meat, seafood, and alcohol, can cause inflammation and exacerbate the signs and symptoms of thumb arthritis. Additionally, thumb arthritis can be accelerated by acute injuries or chronic misuse of the thumb joint. Sports, hard labour, and hobbies that require repetitive thumb motions can all lead to joint irritation and damage over time. Thus, driving the thumb arthritis market revenue.

Thumb Arthritis Market Segment Insights

Thumb Arthritis Diagnosis Insights

The  thumb arthritis market segmentation, based on diagnosis includes Physical Examinations, Imaging, FNA. The imaging segment dominated the market. Thumb arthritis is frequently diagnosed via X-ray imaging. X-rays can reveal indications of joint injury such as bone spurs, changes in the bone's structure, or a narrowing of the joint space. Additionally, X-rays can assist distinguish between various forms of arthritis, such as osteoarthritis and rheumatoid arthritis.

Thumb Arthritis Type Insights

The  thumb arthritis market segmentation, based on type, includes Osteoarthritis, Rheumatoid. The osteoarthritis category generated the most income. It is characterized by the cartilage in these joints gradually deteriorating. Stiffness, edema, discomfort, lack of flexibility, chronic pain, a grating sensation, bone spurs, and sleep disturbances are typical symptoms of OA in thumb. People who have sedentary lifestyles, have poor eating habits, and have higher rates of obesity and blood sugar are more likely to develop OA in thumb. This, combined with the growing senior population, which is more susceptible to such illnesses, is one of the primary factors fueling the market's rise.

Figure 1  Thumb Arthritis Market, by Type, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Thumb Arthritis Treatment Insights

The  thumb arthritis market segmentation, based on treatment, includes Thumb Exercise, Medication, Surgery. The medication category generated the most income. Significant improvements in treatment options, including pharmacological interventions, have been made in the market for thumb arthritis. Increased investment from private & public organisations for the development of the healthcare sector, along with improvements in R&D efforts for drug discovery, are the main factors driving the growth of the osteoarthritis therapeutics market.

For instance, in December 2022, leading science and technology company Merck KGaA has announced a research partnership and commercial licence agreement with Cambridge, Massachusetts-based Mersana Therapeutics, Inc. to develop novel antibody-drug conjugates (ADCs) using Mersana's unique Immunosynthen STING-agonist ADC platform, targeted at up to two targets.

Thumb Arthritis End-Users Insights

The  thumb arthritis market segmentation, based on end-users, includes Hospitals & Clinics, Retail Pharmacies. The hospitals & clinics category generated the most income due to the large number of individuals seeking treatment for thumb arthritis in hospitals and the wide variety of medications for osteoarthritis available in hospital & clinics.

Thumb Arthritis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American thumb arthritis market area will dominate this market as a result of an expanding senior population, a strong healthcare industry, and rising healthcare costs. The presence of advanced economies like the United States and Canada is boosting market expansion in this area. The area is implementing an increasing number of treatments and drugs. In North America, the US will control a substantial percentage of the market for thumb arthritis when compared to Canada and Mexico.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  THUMB ARTHRITIS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe thumb arthritis market accounts for the second-largest market share due to the availability of funding for research, higher surgical adoption rates, and an expanding patient base. Additionally, rising R & D expenditures in disease therapies by local businesses are promoting market expansion in this area. Furthermore, it is projected that government reimbursement policies, increased research and development activities in the production of novel medicines, the launch of new therapies, and the availability of better treatment options would all boost market expansion in the region. Further, the German thumb arthritis market held the largest market share, and the UK thumb arthritis market was the fastest growing market in the European region

The Asia-Pacific thumb arthritis market is expected to grow at the fastest CAGR from 2023 to 2032 due to the rise in the number of elderly and obese people worldwide. The expansion of the healthcare sector in developing nations like China and India is boosting the industry in this area. Additionally, the expansion is a result of rising investment in the healthcare industry, research and development activity, and government backing. Moreover, China’s thumb arthritis market held the largest market share, and the Indian thumb arthritis market was the fastest growing market in the Asia-Pacific region.

Thumb Arthritis Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the thumb arthritis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, thumb arthritis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  thumb arthritis industry to benefit clients and increase the market sector. In recent years, the thumb arthritis industry has offered some of the most significant advantages to market. Major players in the thumb arthritis market attempting to increase market demand by investing in research and development operations include BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

Amgen Inc. is a biotechnology firm that finds, develops, produces, and sells cutting-edge human pharmaceuticals to treat patients with severe diseases. It creates innovative treatments for conditions related to the cardiovascular system, inflammation, oncology/hematology, bone health, neurological problems, and nephrology. The business creates products employing cutting-edge human genetics to comprehend the basics of human biology and analyze the challenges of disease. In the US, Amgen mostly sells its goods to wholesale distributors of pharmaceuticals. Additionally, it uses partnerships with other businesses and direct-to-consumer channels to sell specific products to customers.

AbbVie Inc. is a specialized biopharmaceutical firm that finds, develops, produces, and sells medications for the management of chronic and difficult-to-treat disorders. Its medications are approved for the treatment of cancer, neurological disorders, rheumatoid arthritis, endometriosis pain, pediatric Crohn's disease, metabolic and rheumatological diseases, skin issues, and other significant medical ailments. Additionally, Crohn's disease, Parkinson's disease, viral illnesses, wet AMD, various malignancies, neurological disorders, aesthetic conditions, and other autoimmune diseases are among the pipeline diseases that AbbVie is pushing.

Key Companies in the thumb arthritis market include

• BioPro (U.S.)


• McKie Splints (U.S.)


• AbbVie Inc. (U.S.)


• Hoffmann-La Roche Ltd (Switzerland)


• Amgen Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Carestream Health. (U.S.)


• General Electric Company (U.K)

Thumb Arthritis Industry Developments

February 2023 In an announcement, Roche stated that it had intensified its partnership with Janssen Biotech Inc. (Janssen) to develop companion diagnostics for targeted treatments.

July 2018 A single injectable viscosupplement called MONOVISC is offered by Anika Therapeutics Inc. It contains cross-linked sodium hyaluronate in phosphate-buffered saline solution. This is employed in the treatment of osteoarthritis-related joint pain.

June 2020 One of the top businesses, Horizon Therapeutics Plc (UK), increased its market share in the US.

February 2020 Voltaren was introduced in the US by Glaxosmithkline Plc, the most well-known business.

Thumb Arthritis Market Segmentation

Thumb Arthritis Diagnosis Outlook (USD Billion, 2018-2032)

• Physical Examinations


• Imaging


• FNA

Thumb Arthritis Type Outlook (USD Billion, 2018-2032)

• Osteoarthritis


• Rheumatoid

Thumb Arthritis Treatment Outlook (USD Billion, 2018-2032)

• Thumb Exercise 


• Medication


• Surgery

Thumb Arthritis End Users Outlook (USD Billion, 2018-2032)

• Hospitals & Clinics


• Retail Pharmacies

Thumb Arthritis Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America